Claris Injectibles, a subsidiary of India-based Claris Lifesciences Limited, earned Food and Drug Administration approval for its bupivacaine hydrochloride injectable medication.
Bupivacaine hydrochloride is a long-acting local or regional anesthesia used for surgical procedures.
Claris currently has 15 drug approvals, with 25 pending. The company expects more market approvals before the end of the year.
More articles on the drug market:
FDA expedites Merck's experimental Ebola vaccine
Pills laced with fentanyl invade drug market
Patients in Texas and Florida gain easier access to opioid-overdose antidote naloxone